NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085

New Data Highlighting Foundation Medicine's Next-Generation Sequencing Approach in Clinical Oncology to be Presented at 103rd AACR Annual Meeting 2012

Genomic Profile Demonstrates High Concordance with Existing Commercial Assays and Identifies Broader Range of Actionable Alterations

CAMBRIDGE, Mass., March 27, 2012 – Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new data highlighting the company's next-generation sequencing approach in clinical oncology will be presented at the 103rd American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31 through April 4 in Chicago.

The presentations will highlight the technical feasibility and clinical relevance of the company's next-generation sequencing platform for oncology, which offers a fully informative genomic profile of the relevant alterations present in about 200 genes known to be somatically altered in human cancers. In these studies, the profile demonstrated concordance with existing commercial offerings and identified all classes of genomic alterations. In one study being presented, approximately 70 percent of cases were found to carry one or more actionable alterations, meaning the alteration could plausibly confer sensitivity or resistance to approved or experimental targeted therapies. The studies also identified more classes of alterations, including base pair mutations, insertions and deletions, copy number alterations and select gene fusions and rearrangements, than other commercially available molecular diagnostic tests.

"The data presented at AACR show that the breadth and relevance of Foundation Medicine's genomic profile may offer important information for cancer treatment decisions, while fitting easily into routine clinical practice," said Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine. "These findings support the feasibility of our fundamental mission to help practicing oncologists integrate the unique molecular information for each patient's tumor into clinical decision making."

The schedule for Foundation Medicine's presentations and posters is as follows:

Date & Time: Sunday, April 1, 2012 from 4:05 to 4:20 p.m. (CDT)

Title:	Massively parallel sequencing of cancer FFPE specimens matches diagnostic accuracy of methods in current clinical use and reveals additional actionable mutations
Abstract:	#965
Session:	Minisymposium
Location:	McCormick Place West (Level 1), Room W181
Presenter:	**Michael F. Berger, Ph.D., Memorial Sloan-Kettering Cancer Center** (research in collaboration with Foundation Medicine and University of California San Francisco)
Date & Time:	Sunday, April 1, 2012 from 4:35 to 4:50 p.m. (CDT)
Title:	Massively parallel sequencing of clinical FFPE cancer specimens enables comprehensive genomic assessment of patient eligibility for targeted therapy
Abstract:	#967
Session:	Minisymposium
Location:	McCormick Place West (Level 1), Room W181
Presenter:	**Roman Yelensky, Ph.D., director, clinical genomic analysis, Foundation Medicine**
Date & Time:	Monday April 2, 2012 from 8:00 a.m. to noon (CDT)
Title:	Identification of recurrent oncogenic KIF5B-RET rearrangements in non-small cell lung cancer
Abstract:	#LB-88
Session:	Late-Breaking Poster Session
Location:	McCormick Place West (Hall F), Poster Section 37
Date & Time:	Monday, April 2, 2012 from 2:15 to 2:35 p.m. (CDT)
Title:	Clinical applications of comprehensive genotyping in solid tumors: Obstacles and opportunities
Session:	Current Concepts and Controversies in Diagnostics, Therapeutics, and Prevention
Location:	McCormick Place West (Level 4), Room W470
Presenter:	**Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine**
Date & Time:	Tuesday April 3, 2012 from 8:00 a.m. to noon (CDT)
Title:	QPCR and sequence analysis of DNA template from a microfluidic CTC isolation platform
Abstract:	#4554
Session:	Poster Session: Imaging and Molecular Diagnostics
Location:	McCormick Place West (Hall F), Poster Section 25
Date & Time:	Wednesday April 4, 2012 from 8:00 a.m. to noon (CDT)

Title:	Massively parallel DNA-sequencing of aggressive prostate cancer reveals disease heterogeneity and identifies targetable mutations
Session:	Poster Session: Oncogenomics 1
Abstract:	#5074
Location:	McCormick Place West (Hall F), Poster Section 8

About Foundation Medicine's Comprehensive Cancer Genomic Profile

Foundation Medicine's first clinical product is a fully informative genomic profile that complements traditional cancer treatment decision tools and often expands options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor. The profile is the first commercially available targeted sequencing assay utilizing clinical grade next-generation sequencing (NGS) in routine cancer specimens. Foundation Medicine's assay identifies all classes of genomic alterations (including copy number alterations, insertions, deletions and rearrangements) in approximately 200 cancer-related genes. Genomic profile results are reported to the physician along with targeted therapies and clinical trials that may be relevant to each individual patient based on the most recent scientific and medical research. Foundation Medicine operates a CLIA-certified lab and will formally launch its commercial clinical laboratory services in mid-2012.

About Foundation Medicine

Foundation Medicine is dedicated to improving cancer care through the development of comprehensive cancer diagnostics that will help physicians inform treatment decisions based on an individual patient's molecular cancer subtype. Foundation Medicine's first laboratory developed test, based on a next-generation sequencing platform, is designed to accommodate a broad landscape of cancer genome information and a growing repertoire of targeted treatments and clinical research opportunities. Foundation Medicine's test will assist physicians to make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patient's unique cancer-associated alterations alongside publicly available scientific and medical information. The company's founding advisors are world leaders in genome technology, cancer biology and medical oncology; they, alongside clinicians, biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the company's website at www.foundationmedicine.com.

###